LT3129018T - Nafld ir nash gydymas - Google Patents

Nafld ir nash gydymas

Info

Publication number
LT3129018T
LT3129018T LTEP15728222.9T LT15728222T LT3129018T LT 3129018 T LT3129018 T LT 3129018T LT 15728222 T LT15728222 T LT 15728222T LT 3129018 T LT3129018 T LT 3129018T
Authority
LT
Lithuania
Prior art keywords
nafld
nash treatment
nash
treatment
Prior art date
Application number
LTEP15728222.9T
Other languages
English (en)
Inventor
Brian Roberts
Xueyan Wang
Yun-Jung Choi
David KARPF
Robert Martin
Charles A. Mcwherter
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3129018(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of LT3129018T publication Critical patent/LT3129018T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
LTEP15728222.9T 2014-04-11 2015-04-10 Nafld ir nash gydymas LT3129018T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11
PCT/US2015/025416 WO2015157697A1 (en) 2014-04-11 2015-04-10 Treatment of nafld and nash

Publications (1)

Publication Number Publication Date
LT3129018T true LT3129018T (lt) 2020-01-10

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15728222.9T LT3129018T (lt) 2014-04-11 2015-04-10 Nafld ir nash gydymas

Country Status (27)

Country Link
US (7) US9381181B2 (lt)
EP (1) EP3129018B1 (lt)
JP (1) JP6865038B2 (lt)
KR (1) KR102374499B1 (lt)
CN (1) CN106163508A (lt)
AU (1) AU2015243239B2 (lt)
BR (1) BR112016023269A8 (lt)
CA (1) CA2944139C (lt)
CL (1) CL2016002517A1 (lt)
CY (1) CY1122602T1 (lt)
DK (1) DK3129018T3 (lt)
EA (1) EA036704B1 (lt)
ES (1) ES2764467T3 (lt)
HR (1) HRP20192299T1 (lt)
IL (1) IL248193B (lt)
LT (1) LT3129018T (lt)
MX (1) MX369921B (lt)
NZ (1) NZ724740A (lt)
PH (1) PH12016501978B1 (lt)
PL (1) PL3129018T3 (lt)
PT (1) PT3129018T (lt)
RS (1) RS59637B1 (lt)
SG (1) SG11201608077PA (lt)
SI (1) SI3129018T1 (lt)
SM (1) SMT202000019T1 (lt)
UA (1) UA121208C2 (lt)
WO (1) WO2015157697A1 (lt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010045361A1 (en) 2008-10-17 2010-04-22 Metabolex, Inc. Methods of reducing small, dense ldl particles
WO2010127103A1 (en) 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SI2443246T1 (en) 2009-06-15 2018-05-31 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
WO2014005013A2 (en) 2012-06-29 2014-01-03 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
CN106163508A (zh) * 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
US10174289B2 (en) 2014-05-28 2019-01-08 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CN107530352A (zh) * 2015-03-26 2018-01-02 T3D治疗有限责任公司 使用茚满乙酸衍生物治疗肝病的方法
US20180104201A1 (en) 2015-04-28 2018-04-19 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
CA3016641A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en) * 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
AU2017353982B2 (en) * 2016-11-04 2021-05-06 Children's Hospital Medical Center Liver organoid compositions and methods of making and using same
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
WO2018106628A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
TWI762634B (zh) 2017-05-05 2022-05-01 大陸商上海赫普化醫藥技術有限公司 胺基-芳基-苯甲醯胺化合物及其使用方法
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN111093705A (zh) 2017-09-13 2020-05-01 诺华股份有限公司 包含fxr激动剂的组合
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
EP3701953A4 (en) 2017-10-27 2021-06-16 Samyang Corporation COMPOSITION FOR THE PREVENTION OR RELIEF OF NON-ALCOHOLIC FAT LIVER DISEASE
PT3720431T (pt) 2017-12-06 2024-12-05 Basf As Derivados de ácidos gordos para o tratamento da esteato-hepatite não alcoólica
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20250163421A (ko) 2018-07-26 2025-11-20 칠드런즈 호스피탈 메디칼 센터 간-담도-췌장 조직 및 이를 제조하는 방법
CN112823012A (zh) 2018-09-12 2021-05-18 儿童医院医学中心 用于产生造血干细胞及其衍生物的类器官组合物
HUE067138T2 (hu) 2018-09-24 2024-10-28 Amarin Pharmaceuticals Ie Ltd Módszerek kardiovaszkuláris események veszélyének csökkentésére egy alanyban
AU2019378845A1 (en) * 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
WO2020102351A1 (en) * 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EP3976066A4 (en) 2019-05-31 2023-06-28 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN116350616A (zh) 2019-11-12 2023-06-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
MX2022014238A (es) * 2020-05-13 2023-04-11 Terns Pharmaceuticals Inc Tratamiento combinado de trastornos hepáticos.
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
EP4337184A1 (en) * 2021-05-11 2024-03-20 Genfit Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JP4293636B2 (ja) 1996-02-14 2009-07-08 アイシス・ファーマシューティカルス・インコーポレーテッド 糖修飾ギャップ付オリゴヌクレオチド
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
PL1667964T3 (pl) 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
ES2399721T5 (es) 2004-03-05 2016-05-25 Univ Pennsylvania Métodos para tratar trastornos o enfermedades asociados a la hiperlipidemia e hipercolesterolemia minimizando los efectos adversos
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
WO2010045361A1 (en) 2008-10-17 2010-04-22 Metabolex, Inc. Methods of reducing small, dense ldl particles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP3071198A1 (en) 2013-11-20 2016-09-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
CN106163508A (zh) 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
WO2015200580A1 (en) 2014-06-26 2015-12-30 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia

Also Published As

Publication number Publication date
HRP20192299T1 (hr) 2020-03-06
US20190142776A1 (en) 2019-05-16
SI3129018T1 (sl) 2020-02-28
SMT202000019T1 (it) 2020-03-13
WO2015157697A1 (en) 2015-10-15
US20160324812A1 (en) 2016-11-10
CA2944139A1 (en) 2015-10-15
CA2944139C (en) 2020-11-03
JP6865038B2 (ja) 2021-04-28
US9616039B2 (en) 2017-04-11
US20180008566A1 (en) 2018-01-11
BR112016023269A2 (pt) 2017-08-15
RS59637B1 (sr) 2020-01-31
CL2016002517A1 (es) 2017-05-05
EP3129018A1 (en) 2017-02-15
PH12016501978B1 (en) 2023-07-12
EA036704B1 (ru) 2020-12-10
UA121208C2 (uk) 2020-04-27
US20150290154A1 (en) 2015-10-15
MX2016013375A (es) 2017-02-15
BR112016023269A8 (pt) 2021-06-29
CN106163508A (zh) 2016-11-23
MX369921B (es) 2019-11-26
US20180228752A1 (en) 2018-08-16
KR102374499B1 (ko) 2022-03-14
PT3129018T (pt) 2020-01-15
DK3129018T3 (da) 2020-01-20
SG11201608077PA (en) 2016-10-28
KR20160136451A (ko) 2016-11-29
US11179359B2 (en) 2021-11-23
PL3129018T3 (pl) 2020-05-18
PH12016501978A1 (en) 2016-12-19
AU2015243239B2 (en) 2019-11-14
US10342770B2 (en) 2019-07-09
US20200009092A1 (en) 2020-01-09
ES2764467T3 (es) 2020-06-03
JP2017513836A (ja) 2017-06-01
AU2015243239A1 (en) 2016-10-20
US9381181B2 (en) 2016-07-05
CY1122602T1 (el) 2021-03-12
EP3129018B1 (en) 2019-10-23
US9962346B2 (en) 2018-05-08
NZ724740A (en) 2019-11-29
US10722483B2 (en) 2020-07-28
IL248193B (en) 2019-03-31
US10188620B2 (en) 2019-01-29
EA201692050A1 (ru) 2017-01-30
US20210038546A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
LT3129018T (lt) Nafld ir nash gydymas
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
LT3215532T (lt) Anti-tim3 antikūnai ir jų naudojimo būdai
LT3412302T (lt) Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
IL249292A0 (en) Methods and devices for treating pulmonary edema
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT3099717T (lt) Antikūno molekulės tim-3-čiam ir jų panaudojimas
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
LT3174388T (lt) Augalų naikinimo elektra prietaisas ir būdas
LT3258951T (lt) Anti-pvrig antikūnai ir jų panaudojimo būdai
LT3114884T (lt) Debesų įrenginio identifikavimas ir autentifikavimas
LT3139903T (lt) Vandeninis akių tirpalas ir sausų akių sindromo gydymo būdas
GB201519858D0 (en) Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
LT3331877T (lt) Pirazolpirimidino dariniai ir jų panaudojimas
LT3193611T (lt) Mk2 inhibitoriai ir jų panaudojimas
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
PL3147080T3 (pl) Urządzenie do określania kwalifikacji w mocowaniu kołnierzy i program do określania kwalifikacji w mocowaniu kołnierzy
LT3102555T (lt) Junginių kompozicijos ir jų panaudojimas
LT3105253T (lt) Antikūnai prieš jagged1 ir jų naudojimo būdai
GB201404470D0 (en) Therapeutic methods and materials
LT3319612T (lt) Oksisteroliai ir jų naudojimo būdai
LT3498292T (lt) Uspa2 baltymo konstruktai ir jų panaudojimas
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
BR112017002074A2 (pt) vestuário e método de compressão médica terapêutica
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf